{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T13:00:52Z","timestamp":1790600452859,"version":"4.1.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.clgc.2026.102662","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T16:12:34Z","timestamp":1788538354000},"page":"102662","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical Outcomes of Neuroendocrine Prostate Cancer Treated With Platinum-Based Chemotherapy: A Single-Institution Experience"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0168-2069","authenticated-orcid":false,"given":"Christopher E.","family":"Wee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5181-490X","authenticated-orcid":false,"given":"Amanda","family":"Nizam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0184-3467","authenticated-orcid":false,"given":"Moshe C.","family":"Ornstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7959-5040","authenticated-orcid":false,"given":"Yanwen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santosh","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2161-9465","authenticated-orcid":false,"given":"Demetrios","family":"Dedousis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy D.","family":"Gilligan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shalini","family":"Moningi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0969-6422","authenticated-orcid":false,"given":"Rebecca","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shilpa","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Pt 3","key":"10.1016\/j.clgc.2026.102662_bib0001","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.semcancer.2022.05.007","article-title":"Molecular mechanisms underlying the development of neuroendocrine prostate cancer","volume":"86","author":"Liu","year":"2022","journal-title":"Semin Cancer Biol"},{"issue":"5","key":"10.1016\/j.clgc.2026.102662_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2017.04.006","article-title":"Contemporary incidence and cancer control outcomes of primary neuroendocrine prostate cancer: a SEER database analysis","volume":"15","author":"Zaffuto","year":"2017","journal-title":"Clin Genitourin Cancer"},{"issue":"16","key":"10.1016\/j.clgc.2026.102662_bib0003","doi-asserted-by":"crossref","first-page":"4874","DOI":"10.3390\/jcm13164874","article-title":"Prognostic nomogram predicting survival and propensity score matching with demographics and comparative analysis of prostate small cell and large cell neuroendocrine carcinoma","volume":"13","author":"Ullah","year":"2024","journal-title":"J Clin Med"},{"issue":"2","key":"10.1016\/j.clgc.2026.102662_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2014.06.006","article-title":"Metastatic small cell carcinoma of the prostate: population-based analysis of patient characteristics and treatment paradigms","volume":"33","author":"Cohen","year":"2015","journal-title":"Urol Oncol"},{"key":"10.1016\/j.clgc.2026.102662_sbref0005","series-title":"NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Version 5.2026","year":"2026"},{"issue":"20","key":"10.1016\/j.clgc.2026.102662_bib0006","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1200\/JCO-25-00007","article-title":"Systemic therapy in patients with metastatic castration-resistant prostate cancer: ASCO guideline update","volume":"43","author":"Garje","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2026.102662_bib0007","series-title":"R: A Language and Environment for Statistical Computing. Version 4.6.0","year":"2026"},{"key":"10.1016\/j.clgc.2026.102662_bib0008","unstructured":"SAS Institute Inc. SAS Software, Version 9.4. Cary, NC: SAS Institute Inc; 2013."},{"issue":"3","key":"10.1016\/j.clgc.2026.102662_bib0009","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/pcan.2014.26","article-title":"Population-based analysis of treatment modalities and survival for clinically localized small-cell carcinoma of the prostate","volume":"17","author":"Weiner","year":"2014","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"16 Suppl","key":"10.1016\/j.clgc.2026.102662_bib0010","article-title":"Difference in survival outcomes between de novo vs therapy-related neuroendocrine cancer of prostate (NCP): a SEER-based analysis","volume":"43","author":"Juthani","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2026.102662_bib0011","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ejca.2019.08.011","article-title":"Clinical features of neuroendocrine prostate cancer","volume":"121","author":"Conteduca","year":"2019","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.clgc.2026.102662_bib0012","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1002\/pros.24664","article-title":"Diagnosis and management of neuroendocrine prostate cancer","volume":"84","author":"de Kouchkovsky","year":"2024","journal-title":"Prostate"},{"issue":"5","key":"10.1016\/j.clgc.2026.102662_bib0013","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.annonc.2026.01.015","article-title":"Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"37","author":"Fizazi","year":"2026","journal-title":"Ann Oncol"},{"issue":"13","key":"10.1016\/j.clgc.2026.102662_bib0014","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1158\/1078-0432.CCR-12-3791","article-title":"Platinum-based chemotherapy for variant castrate-resistant prostate cancer","volume":"19","author":"Aparicio","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"10212","key":"10.1016\/j.clgc.2026.102662_bib0015","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.clgc.2026.102662_bib0016","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N Engl J Med"},{"issue":"16 Suppl","key":"10.1016\/j.clgc.2026.102662_bib0017","doi-asserted-by":"crossref","first-page":"5016","DOI":"10.1200\/JCO.2026.44.16_suppl.5016","article-title":"Phase 2 multicenter trial of chemoimmunotherapy for patients with neuroendocrine or aggressive variant metastatic prostate cancer (CHAMP)","volume":"44","author":"Armstrong","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2026.102662_bib0018","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1186\/s12885-023-11473-2","article-title":"Effect of chemotherapy alone or combined with immunotherapy for locally advanced or metastatic genitourinary small cell carcinoma: a real-world retrospective study","volume":"23","author":"Huang","year":"2023","journal-title":"BMC Cancer"},{"issue":"16 Suppl","key":"10.1016\/j.clgc.2026.102662_bib0019","doi-asserted-by":"crossref","first-page":"5059","DOI":"10.1200\/JCO.2025.43.16_suppl.5059","article-title":"Phase 1b\/2 KEYNOTE-365 cohort I: pembrolizumab plus carboplatin and etoposide chemotherapy or chemotherapy alone for metastatic neuroendocrine prostate cancer (NEPC)","volume":"43","author":"von Amsberg","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2026.102662_sbref0020","series-title":"NCCN Clinical Practice Guidelines in Oncology: Neuroendocrine and Adrenal Tumors. Version 1.2026","year":"2026"},{"issue":"13","key":"10.1016\/j.clgc.2026.102662_bib0021","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1002\/pros.24189","article-title":"Chemotherapy with atezolizumab for small cell or neuroendocrine carcinoma of the prostate: a single institution experience","volume":"81","author":"Wee","year":"2021","journal-title":"Prostate"},{"issue":"18","key":"10.1016\/j.clgc.2026.102662_bib0022","doi-asserted-by":"crossref","first-page":"3854","DOI":"10.1158\/1078-0432.CCR-25-1211","article-title":"Safety and efficacy of tarlatamab in patients with neuroendocrine prostate cancer: results from the phase 1b DeLLpro-300 study","volume":"31","author":"Aggarwal","year":"2025","journal-title":"Clin Cancer Res"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155876732600162X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155876732600162X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T12:38:29Z","timestamp":1790599109000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S155876732600162X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":22,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S155876732600162X"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102662","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Outcomes of Neuroendocrine Prostate Cancer Treated With Platinum-Based Chemotherapy: A Single-Institution Experience","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102662","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102662"}}